EGFR and non-small cell lung carcinoma: Although third-generation EGFR-TKIs Almonertinib approved in China was effective in improving ORR and DCR of brain metastatic lesions in EGFR-mutated NSCLC patients [22], what kind of treatment options should be chosen after its resistance is still worth further exploration.